Evaluation of GSK4527363 in Systemic Lupus Erythematosus and Healthy Participants, Including Chinese and Japanese Cohorts

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of **GSK4527363** in participants with **Systemic Lupus Erythematosus** (SLE) as well as in healthy participants, including those of Chinese and Japanese descent. This is clinically relevant as it aims to understand the potential therapeutic effects and safety profile of GSK4527363 in a diverse population, which is crucial for the development of effective treatments for SLE, a chronic autoimmune disease characterized by inflammation and tissue damage in various organs.

The clinical trial involves a total of **19 participants** diagnosed with **Systemic Lupus Erythematosus**. The study population includes both male and female subjects, with an age range encompassing adults and adolescents. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The selection process aimed to ensure a representative sample of individuals affected by the condition under investigation.

The clinical trial is designed to evaluate the safety and efficacy of **GSK4527363** in participants with **Systemic Lupus Erythematosus** (SLE) as well as in healthy individuals, including those of Chinese and Japanese descent. This is a Phase 1 trial, which is typically the first stage of testing in human subjects and primarily focuses on assessing the safety profile of the investigational product. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on July 7, 2025, to the anticipated end date on May 14, 2027.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment, including medical history review and necessary laboratory tests. Following successful screening, participants will be randomized into different study arms. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' health status, collect data on the investigational product's effects, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather data on long-term safety and efficacy outcomes.

The expected length of participant involvement will vary depending on the specific study arm and individual response to the investigational product. Participants may be withdrawn from the study prematurely if they experience adverse events that compromise their safety, fail to comply with the study protocol, or choose to withdraw consent. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the available data. Information on parameters or endpoints, methods, schedules, or tools for efficacy assessment is not included. The trial is identified as a Phase 1 study, with an estimated recruitment start date of July 7, 2025, and an estimated end date of May 14, 2027. Further details on efficacy evaluation are not available in the provided source.